Treatment With hOKT3gamma1(Ala-Ala) in T1DM

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
This is a phase II study to examine the clinical and immunological effects of humanized FcR non-binding anti-CD3 mAb in participants with Type 1 diabetes mellitus (T1DM), and to develop this therapy to prevent the immune destruction leading to β cell loss.
Epistemonikos ID: f54d182acbba8a64a898190c5e6264af31ca8176
First added on: May 05, 2024